Cardiovascular disease (CVD) is the leading cause of morbidity and mortality for both men and women among all ethnicities worldwide. Although significant improvements in the management of CVD occurred in the 20th century, non-invasive, universal, early diagnostic biomarkers and newer therapeutic drugs are needed for clinical treatment by physicians. MicroRNAs (miRNAs) are a class of endogenous, non-coding, single-stranded, small RNA molecules that are critically controlled by all human biological processes. Moreover, dysregulated miRNA expression is directly involved in various CVDs, including stable coronary artery disease and acute coronary syndrome. Several miRNAs that are enriched in the plasma of CVD patients have potential as clinical biomarkers, and overexpression or inhibition of specific miRNAs has novel therapeutic significance in the management of CVD. Aging is a multifactorial physiological process that gradually deteriorates tissue and organ function and is considered a non-modifiable major risk factor for CVDs. Recently, several studies established that various miRNAs essentially regulate aging and aging-related disease processes. This narrative review briefly discusses the recently updated molecular involvement of miRNAs in CVDs, their possible diagnostic, prognostic, and therapeutic value, and their relationship to the aging process.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459564 | PMC |
http://dx.doi.org/10.1177/03000605241279190 | DOI Listing |
J Family Med Prim Care
December 2024
Department of Orthopedics, B.J Medical College, Ahmedabad, Gujarat, India.
Background: Cardiovascular diseases (CVDs) are one of the most prevalent causes of mortality worldwide, especially significant in low- and middle-income countries. Kyrgyzstan and India represent such nations that face a huge burden of CVD-related deaths globally. Understanding the prevalence of traditional cardiovascular risk factors (CVRFs) in these populations is critical for effective prevention and management strategies.
View Article and Find Full Text PDFJ Family Med Prim Care
December 2024
Department of Family Medicine, Head Quarters Hospital, Cuddalore, Tamil Nadu, India.
Background: India is witnessing a significant increase in the prevalence of non-communicable diseases (NCDs), and addressing this requires a comprehensive and multi-faceted approach. The burden of NCDs puts a strain on the healthcare system, requiring an increased focus on preventive measures, early detection, and management of chronic conditions. Adopting a risk-based approach to cardiovascular diseases (CVDs) in resource-poor settings offers several economic and social advantages.
View Article and Find Full Text PDFCardiovasc Diagn Ther
December 2024
Department of Cardiology, University Heart & Vascular Center, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Background: Cardiovascular disease (CVD) remains the leading cause of death in pregnant and peripartal women in western countries. Physiological changes during pregnancy can lead to cardiovascular complications in the mother; women with pre-existing heart disease may not tolerate these changes well, increasing their susceptibility to adverse cardiovascular outcomes during pregnancy. The aim of this study is to characterize pregnancy-induced changes in cardiac function, biomarker concentrations and cardiovascular outcomes in women with CVD during pregnancy at a tertiary care hospital in Germany.
View Article and Find Full Text PDFBMC Med Res Methodol
January 2025
School of Mathematical Sciences, Xiamen University, Xiamen, 361005, People's Republic of China.
Objective: To assess whether the outcome generation true model could be identified from other candidate models for clinical practice with current conventional model performance measures considering various simulation scenarios and a CVD risk prediction as exemplar.
Study Design And Setting: Thousands of scenarios of true models were used to simulate clinical data, various candidate models and true models were trained on training datasets and then compared on testing datasets with 25 conventional use model performance measures. This consists of univariate simulation (179.
Sci Rep
January 2025
Xiyuan Hospital, China Academy of Chinese Medicine Sciences, Beijing, 100091, China.
Identifying dependable prognostic indicators is essential for the efficient management of metabolic dysfunction-associated steatotic liver disease (MASLD). The index of hemoglobin glycation (HGI) has been demonstrated to be closely linked to the onset and advancement of MASLD. Currently, no studies have investigated the relationship between HGI and mortality rates among MASLD patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!